Navigation Links
Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets
Date:7/7/2008

SAN DIEGO, July 7 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL) today announced that it has come to an agreement with its secured creditors, General Electric Capital Corporation and Oxford Financial Corporation (Lenders). The agreement follows Favrille's recent announcement that the Lenders had received approximately $8.8 million as repayment of the outstanding principal, accrued interest and certain costs. Acceleration of the loan was triggered when the Company's cash fell below the $14.5 million minimum cash covenant on May 30, 2008. Under terms of the agreement, the Company reimbursed the Lenders an additional $47,000 of transaction costs. The Lenders have been paid in full and, therefore, have agreed to release the general lien on the Company's assets.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO)

Following the recent announcement that the Phase 3 registration trial for its lead product, Specifid(TM), failed to demonstrate activity, Favrille announced it would cease all activities related to Specifid and other programs requiring production of patient-specific therapies including the T-cell and autoimmune disease programs. The Company laid off 132 of its 144 employees, including six of its eight executive officers, effective June 6, 2008. In addition, the Company plans to sell all unneeded fixed assets in the near future.

Favrille is currently in discussions with its landlord regarding the terms of the existing lease agreement in light of the fact that the Company does not require, nor can it meet the obligations for, the GMP manufacturing facility designed for the manufacture of Specifid. The Company intends to maximize the value of its other assets, including the panel of humanized anti-CD20 antibodies acquired from Diversa (now Verenium) in 2007.

"We have received a number of inquiries regarding the manufacturing fa
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
2. Favrille CEO to Present at Bear Stearns Healthcare Conference
3. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
4. Favrille to Present at BIO InvestorForum
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
7. Favrille Announces $21.1 Million Registered Direct Offering
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
10. Favrille Reports First Quarter 2008 Financial Results
11. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... MN , May 1, 2015 /PRNewswire/ - BioAmber ... producing sustainable chemicals, today announced that it has priced an ... stock at a price of $9.00 per share, and ... to purchase up to an additional 585,000 shares of ... will be $35.1 million.  The offering is expected to close ...
(Date:5/1/2015)... 1, 2015 /CNW/ - Softchoice, a leading North American IT solutions ... proud recipient of two Cisco® Partner Summit Country awards. ... Year and Security Partner of the Year for ... this week in Montreal . ... Cisco partner awards at this year,s conference," said David ...
(Date:5/1/2015)... 1, 2015 Investor-Edge has ... Ltd (NASDAQ: GENE ), Agilent Technologies Inc. ... (NYSE: TMO ), Sequenom Inc. (NASDAQ: ... ). Free research report on Genetic Technologies can ... April 30, 2015, the NASDAQ Composite ended at ...
(Date:5/1/2015)... DALLAS , May 1, 2015 ... report "Antibody Production Market by Product (Equipment, Consumables), by ... (Biopharmaceutical Companies, Diagnostic Labs, Research Institutes) - Analysis ... the report studies the global Antibody Production Market ... This market is expected to reach $2.572 Billion ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4
... Riordan Clinic scientists Dr. Nina Mikirova, Dr. ... new technology that may help doctors determine the severity ... in the January/February issue of the journal, Alternative ... Metabolism in Patients with Chronic Fatigue Syndrome by Serum ...
... 11, 2012  Ikaria, Inc., a critical care company ... critically ill patients, today announced that Joseph Stauffer, ... this role, Dr. Stauffer will be responsible for ... activities related to Ikaria,s commercialized product, INOMAX® (nitric ...
... 2012 Narayana Hrudayalaya Hospitals of India has ... of the United States to bring innovative healthcare ... Hrudayalaya Hospitals (NH) is led by Chairman and ... cardiovascular surgeon with extensive experience in providing high-quality/low-cost ...
Cached Biology Technology:Riordan Clinic Research Institute Has Developed and Patented a Process for the Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome 2Riordan Clinic Research Institute Has Developed and Patented a Process for the Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome 3Ikaria® Appoints Chief Medical Officer 2Ikaria® Appoints Chief Medical Officer 3Narayana Hrudayalaya Hospitals Teams With Ascension Health Alliance to Build Health City at Grand Cayman 2Narayana Hrudayalaya Hospitals Teams With Ascension Health Alliance to Build Health City at Grand Cayman 3Narayana Hrudayalaya Hospitals Teams With Ascension Health Alliance to Build Health City at Grand Cayman 4
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/2/2015)... , April 2, 2015 At its ... Salt Lake City , the American College of ... five new directors to its Board.  Members of the ... ACMG and for forming and advancing its policies and ... genetics profession. "It,s an eventful time in ...
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... studying the reliability of species distribution models for ... have focused their research on the endangered marsupial, ... Ecography demonstrates that studying weather events, rather ... a clearer insight into the Bettong,s movements, range ...
... BRUNSWICK, N.J. The National Institutes of Health (NIH) ... quick and economical analysis of tissue from breast cancer ... a common form of breast cancer is likely to ... minimize side effects. The NIH made its grant ...
... Large, persistent populations of genetically engineered canola ... North Dakota. As genetically engineered crops become increasingly ... potential ecological side effects. A study published ... reports that genetically engineered canola endowed with ...
Cached Biology News:Australia's endangered bettong reveals how weather effects species distribution 2Rutgers-affiliated company receives funding for technology to help choose breast cancer treatments 2Rutgers-affiliated company receives funding for technology to help choose breast cancer treatments 3
Normal serum collected from healthy Kunming mice....
Request Info...
QML offers standard and customized paraffin embedded tissue blocks....
Use our experts and resources to develop reagent systems for your applications....
Biology Products: